Abivax S.A.ABVX
Price (close)
$91.06
Market cap
$7.2B
P/E
—
Revenue (FY)
$4.6M
Net income
-$336.1M
Dividend yield
—
1-year total return
11.0%
Net margin
-7354.5%
Revenue growth
-63.3%
Debt / equity
—
What Abivax S.A. does.
(a) % Difference is for ABX464 minus placebo and is based on estimated common risk difference using the Mantel-Haenszel weights adjusting
for the randomization stratification f actors: inadequate response to advanced therapies (yes/no), Baseline oral corticosteroids usage (yes/no). P-
values are two sided. NRI is used for subjects with missing outcome at Week 8 and subjects reporting any IE prior to Week 8.
Revenue and profit, by fiscal year.
| Fiscal year | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|
| Revenue | — | $12.0M | $4.6M | $4.6M | $12.4M | $4.6M |
| Net income | — | -$42.5M | -$60.7M | -$147.7M | -$176.2M | -$336.1M |
| Free cash flow | — | -$45.1M | -$54.2M | -$97.4M | -$154.7M | -$161.3M |
More on ABVX.
- Abivax S.A. summary
- Abivax S.A. financial statements
- Abivax S.A. key metrics
- Abivax S.A. health scores and style box
- Abivax S.A. earnings
- Abivax S.A. dividends
- Abivax S.A. valuation
- Abivax S.A. ownership and insiders
- Abivax S.A. peers
Figures from Abivax S.A.'s filings with the U.S. SEC, standardised automatically; prices are end-of-day closes. Not financial advice.